<DOC>
	<DOCNO>NCT00240526</DOCNO>
	<brief_summary>To evaluate persistence anti-HBs antibody 16 , 17 , 18 , 19 20 year administration first dose study vaccine . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 . No additional subject recruit long-term follow-up study vaccine administer .</brief_summary>
	<brief_title>LT F-up Study 16-20 Yrs After Vaccine Dose Hepatitis B With/Without HBIg Newborns HBeAg+ Mothers</brief_title>
	<detailed_description>The primary study evaluate reactogenicity , immunogenicity protective efficacy hepatitis B vaccine healthy neonate HBeAg positive mother administer without dose HBIg birth . The current study describes long term follow subject Y16 20 primary vaccination .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Subjects receive least one dose study vaccine primary study Written inform consent obtain subject blood sample visit</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Hepatitis B immunoglobulin</keyword>
	<keyword>Hepatitis B antibody persistence</keyword>
</DOC>